[The relevance of multiple sclerosis drugs in private health insurance (PHI)].
The development of expenses and prescriptions in the pharmacotherapy for multiple sclerosis (MS) is examined on the basis of prescription data of 14 PHI firms. The drugs for the treatment of MS are among the most top-selling drugs in the PHI. From 2007 to 2012, the expenses increase 2.33-fold. The main cause is the increas of the prescription figures. In 2012, about 8,400 privately insured persons receive an MS drug. The prevalence of MS is 2.3 times higher in women than in men Impro ved diagnostic possibilities and expensive new drugs will lead to a dynamic cost de velopment in the next years.
F
F
Wild
D003363:Cost Control / Q000639:trends; D003430:Cross-Sectional Studies; D016527:Drug Costs / Q000639:trends*; D005260:Female; D005544:Forecasting; D005858:Germany; D006801:Humans; D007155:Immunologic Factors / Q000191:economics* / Q000627:therapeutic use*; D007356:Insurance, Pharmaceutical Services / Q000191:economics* / Q000639:trends; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000191:economics* / Q000453:epidemiology
D007155:Immunologic Factors